Promote Corneal Healing with Opticyte Amniotic Ocular Matrix

Merakris Therapeutics ocular tissue technology is based on a sophisticated and delicate manufacturing process intended to retain extracellular matrix properties and structures. This makes it ideal for ocular applications.

  • Processed without harsh chemical reagents that may cause irritation when placed in the corneal bed.
  • Opticyte Matrix provides an ophthalmic barrier to the corneal surface and supports cell attachment and ingrowth.
  • Minimal scarring is observed in Opticyte Matrix-protected corneas during healing and re-epithelialization

And the Merakris difference means the highest quality products, fast shipments, technical support and reimbursement guidance.

Merakris offers a comprehensive Reimbursement Guide for providers using Opticyte.

To get your copy, complete this form and we'll be in touch shortly.

Reimbursement Guide Request

Opticyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1270 and 1271.